We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
By Laura Kusisto and Ruth Bender
ST. LOUIS -- The latest trial over allegations that Bayer AG's popular Roundup weedkiller causes cancer was postponed indefinitely at the last minute on Friday to allow room for escalating settlement talks to continue.
Bayer was hours away from facing another jury on the issue, after the German chemical and drug conglomerate over the last year and a half lost the first three Roundup trials for a total of $190.5 million in awards. A fourth adverse verdict could have handed plaintiffs, who number more than 42,000, additional ammunition in settlement talks that have dragged on for months.
Analysts estimate any settlement would be in the $8 billion to $12 billion range, in talks led by court-appointed mediator Ken Feinberg, who said he was "cautiously optimistic" a deal could be struck in the coming weeks.
A Friday order from Judge Elizabeth Hogan said simply "cause(sic) continued" in handwritten print. A Bayer spokesman confirmed the case is delayed indefinitely, "to provide room for the parties to continue the mediation process in good faith ... and avoid the distractions that can arise from trials."
He added that, "there is no comprehensive agreement at this time. There also is no certainty or timetable for a comprehensive resolution."
(END) Dow Jones Newswires
January 24, 2020 15:06 ET (20:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions